Xenon Pharmaceuticals (NASDAQ:XENE) Sees Strong Trading Volume - What's Next?
Xenon Pharmaceuticals (NASDAQ: XENE) experienced unusually high trading volume, with mid-day activity showing a 30% decline from the previous session, closing at $56.5950. Despite this, analysts maintain a "Buy" consensus rating with an average price target of $71.88, reflecting optimism in the stock. However, significant insider selling, including 270,000 shares by CEO Ian Mortimer, contrasts with this positive analyst outlook.
Aberdeen Group plc Increases Stock Position in Xenon Pharmaceuticals Inc. $XENE
Aberdeen Group plc significantly increased its stake in Xenon Pharmaceuticals Inc. by 29.6% in the fourth quarter, bringing its total holdings to 750,291 shares valued at approximately $33.63 million. This strategic move comes amidst notable insider selling from the company's CEO and other executives, with insiders having sold over $17.8 million worth of stock in the past 90 days. Despite the insider sales, Wall Street analysts maintain a largely positive outlook on Xenon Pharmaceuticals, with an average "Buy" rating and a target price of $71.88.
XENE Financials: Revenue Breakdown, Margins & Competitor Comparison
This article provides a financial overview of Xenon Pharmaceuticals Inc (XENE), detailing its profitability margins and comparing them to competitors TGTX and RYTM. It highlights XENE's impressive 100.00% gross margin but notes negative operating and net margins. The article also mentions the company's market capitalization and Return on Equity.
Xenon Pharmaceut (XENE) SEC Filings - 10-K, 10-Q, 8-K Forms
This page provides a comprehensive resource for Xenon Pharmaceuticals (XENE) SEC filings, including 10-K, 10-Q, 8-K reports, and insider trading forms, with updates from EDGAR. It details recent material events such as the appointment of a new CFO with associated equity awards and insider transactions. The company, a neuroscience-focused biopharmaceutical firm, uses these filings to disclose financial results, executive changes, and updates on its Phase 3 clinical programs for epilepsy and mood disorders.
XENE SEC Filings - Xenon Pharmaceut 10-K, 10-Q, 8-K Forms
This page provides access to SEC filings for Xenon Pharmaceuticals Inc. (XENE), a biopharmaceutical company focused on neuroscience. It details various regulatory documents including 10-K, 10-Q, 8-K forms, and insider trading reports. The platform offers AI-powered summaries of these filings to help investors understand key points related to Xenon’s clinical pipeline, executive changes, and financial disclosures.
Xenon Pharmaceuticals Target of Unusually High Options Trading (NASDAQ:XENE)
Xenon Pharmaceuticals (NASDAQ:XENE) experienced unusually high options trading on Wednesday, with put options increasing by 2,362%, indicating potential bearish sentiment or hedging. Despite recent insider selling totaling $19.6 million over 90 days, analysts broadly rate the stock as a "Buy" with a consensus price target of $71.88. The company, a clinical-stage biopharmaceutical firm, focuses on neurological and pain disorders by targeting ion channels.
XENE SEC Filings - Xenon Pharmaceut 10-K, 10-Q, 8-K Forms
This page provides access to SEC filings for Xenon Pharmaceuticals Inc. (XENE), a neuroscience-focused biopharmaceutical company. It includes 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms, with AI-powered summaries. Recent filings detail the company's financial performance, executive equity awards, and late-stage clinical programs for azetukalner in epilepsy and mood disorders.
How Positive Phase 3 Azetukalner Results and Upsized Financing Could Reframe Xenon Pharmaceuticals (XENE) Investors
Xenon Pharmaceuticals (XENE) has seen positive Phase 3 results for its lead candidate azetukalner and completed a significant US$750 million equity raise, strengthening its financial position ahead of regulatory submissions. While the recent insider stock sale was routine, the company's focus remains on upcoming regulatory milestones and clinical readouts, with a projected revenue of $284.9 million by 2028. Investors should consider both the bullish outlook from analysts and the potential need for additional capital if commercialization is slower than anticipated.
Assessing Xenon Pharmaceuticals (XENE) Valuation After Positive Phase 3 Results And US$750 Million Capital Raise
Xenon Pharmaceuticals (XENE) recently reported positive Phase 3 results for its drug azetukalner and raised US$750 million in a public offering. While the company has seen strong share price momentum and is considered undervalued by some analysts with a fair value of $100, its P/B ratio of 8.9x is significantly higher than the US biotech average. Investors are encouraged to conduct their own analysis given the split sentiment on investment opportunity versus risk.
Xenon Pharmaceuticals (NASDAQ:XENE) Stock Price Crosses Above Fifty Day Moving Average - Time to Sell?
Xenon Pharmaceuticals (NASDAQ:XENE) stock recently crossed above its fifty-day moving average, trading at $54.48 on heavy volume. While analysts maintain a "Buy" consensus rating with a target price of $71.88, insider selling, including a significant transaction by the CEO, indicates some caution. Institutional ownership remains high at 95.45%, suggesting continued confidence from large investors despite insider divestments.
Xenon Pharmaceuticals (XENE) price target increased by 41.64% to 80.01
This article reports a significant increase in the price target for Xenon Pharmaceuticals (XENE), which rose by 41.64% to reach $80.01. This suggests a strong positive outlook from analysts regarding the company's future stock performance and valuation. The specific reasons or analyst firm behind this target increase are not detailed in this snippet.
Xenon Pharmaceuticals (XENE) price target increased by 41.64% to 80.01
This article reports a significant increase in the price target for Xenon Pharmaceuticals (XENE). The target has been raised by 41.64% to $80.01.
Xenon Pharmaceuticals stock soars 20% in 3 months: Here's why
The article explains the reasons behind the 20% surge in Xenon Pharmaceuticals stock over the past three months. This significant increase in stock value is detailed, providing insights into the company's recent performance and potential contributing factors.
Xenon Pharmaceuticals (XENE) climbs 31.7% as epilepsy treatment moves forward
Xenon Pharmaceuticals (XENE) stock surged by 31.7% due to positive developments regarding its epilepsy treatment. The shares experienced significant upward movement based on investor optimism. This indicates a favorable market reaction to the progress of the company's therapeutic pipeline.
JPMorgan Chase & Co. Purchases 142,452 Shares of Xenon Pharmaceuticals Inc. $XENE
JPMorgan Chase & Co. has increased its stake in Xenon Pharmaceuticals (NASDAQ:XENE) by 11.3%, acquiring an additional 142,452 shares to bring its total holding to 1,399,033 shares, valued at approximately $56.17 million. Despite significant insider selling totaling over $19 million in the last 90 days, institutional investors and hedge funds now own 95.45% of the biopharmaceutical company's stock. Analysts maintain a consensus "Buy" rating for XENE, with an average price target of $71.88, although the company recently missed quarterly EPS estimates.
Xenon Pharmaceuticals Stock Soars 20% in 3 Months: Here's Why
Xenon Pharmaceuticals (XENE) shares have climbed 20% in the last three months due to positive top-line data from its X-TOLE2 study for azetukalner, a lead candidate for focal onset seizures. The company plans to submit a new drug application to the FDA in Q3 2026, leveraging the drug's differentiated profile and potential as the only KV7 potassium channel opener for epilepsy. Azetukalner is also being developed for other neurological disorders, including major depressive disorder and bipolar depression, and Xenon has other pipeline assets in early-stage studies.
Xenon Pharmaceuticals Shares Jump 20% Over Three Months: The Reasons Explained
Xenon Pharmaceuticals' stock (XENE) has surged by 20% in the last quarter, primarily due to positive top-line results from its X-TOLE2 trial for azetukalner, a drug targeting focal onset seizures. The company plans to file a new drug application with the FDA in Q3 2026, and is also exploring azetukalner's potential for other neurological conditions like major depressive disorder. Xenon's expanded pipeline and favorable analyst ratings contribute to continued investor optimism.
Xenon Pharmaceuticals Shares Jump 20% Over Three Months: The Reasons Explained
Xenon Pharmaceuticals (XENE) has seen its shares jump 20% over the last three months, primarily due to positive top-line results from its X-TOLE2 trial for azetukalner, a drug candidate for focal onset seizures. The company plans to file a new drug application with the FDA in Q3 2026, positioning azetukalner as a promising treatment. Xenon is also exploring azetukalner's potential in other neurological conditions and advancing other drug candidates in its pipeline, leading to significant investor optimism.
Xenon Pharmaceuticals (XENE) Is Down 6.7% After Major Equity Raise Post X-TOLE2 Data - Has The Bull Case Changed?
Xenon Pharmaceuticals recently completed a US$650 million equity offering after announcing positive Phase 3 X-TOLE2 results for azetukalner, designed to treat focal onset seizures. While the data materially de-risks the clinical narrative for the drug, the equity raise has diluted existing shareholders. The company projects significant revenue and earnings growth by 2028, with fair value estimates aligning with its current price.
Xenon Pharmaceuticals (XENE) Is Down 6.7% After Major Equity Raise Post X-TOLE2 Data - Has The Bull Case Changed?
Xenon Pharmaceuticals recently completed a US$650 million equity offering after reporting positive Phase 3 X-TOLE2 data for azetukalner, designed to treat focal onset seizures. The successful trial de-risks the clinical aspect of azetukalner, positioning it as a potential first-in-class treatment and strengthening Xenon's plan to file a US NDA. However, existing shareholders have been diluted, and the company's investment narrative now hinges on effective commercialization and regulatory approval.
Xenon Pharmaceuticals (XENE) Is Down 6.7% After $650 Million Follow-On Offering And Phase 3 Epilepsy Win
Xenon Pharmaceuticals (XENE) recently completed a $650 million follow-on equity offering to fund its neurology pipeline, shortly after its lead candidate, azetukalner, showed significant success in a Phase 3 epilepsy trial. Despite the positive trial results and reduced financing risk, the stock dropped 6.7% due to the dilutive effect of the offering. The company plans to submit a U.S. FDA NDA for azetukalner in Q3 2026.
XENE Technical Analysis & Stock Price Forecast
The article provides a technical analysis and stock price forecast for Xenon Pharmaceuticals Inc (XENE), indicating a "Strong Buy" consensus based on aggregated technical signals. It details momentum indicators like RSI and MACD, support and resistance levels, and performance relative to various moving averages. The analysis suggests XENE is in neutral territory regarding RSI but shows strong buy signals from MACD and overall moving averages.
Holocene Advisors LP Acquires 167,078 Shares of Xenon Pharmaceuticals Inc. $XENE
Holocene Advisors LP increased its stake in Xenon Pharmaceuticals Inc. by 9.2%, acquiring an additional 167,078 shares to reach a total of 1,976,553 shares valued at approximately $79.36 million. This comes amidst other institutional investor activity and significant insider selling, including CEO Ian Mortimer who sold 270,000 shares worth $16.29 million, reducing his holding to just 6,000 shares. Despite insider sales, analysts generally maintain a "Buy" rating for XENE, with an average target price of $71.88.
Xenon Pharmaceuticals Inc. $XENE Shares Sold by Granahan Investment Management LLC
Granahan Investment Management LLC significantly reduced its holdings in Xenon Pharmaceuticals Inc. (NASDAQ:XENE) by 63.6% in the third quarter, selling 152,568 shares. Despite this, other institutions increased their stakes, and analysts have issued mostly positive ratings for the biopharmaceutical company. Xenon Pharmaceuticals reported a wider-than-expected loss in its last earnings call, and insiders have also sold shares recently, though the company maintains a "Buy" rating with an average target price of $71.88.
Jain Global LLC Takes Position in Xenon Pharmaceuticals Inc. $XENE
Jain Global LLC has acquired a new stake of 252,379 shares in Xenon Pharmaceuticals Inc. (NASDAQ:XENE) during the third quarter, valued at approximately $10.13 million. This purchase makes Jain Global LLC own about 0.33% of the biopharmaceutical company's outstanding stock. Other institutional investors have also increased their holdings in Xenon Pharmaceuticals, which currently has a consensus "Buy" rating from analysts with an average price target of $71.88.
Cinctive Capital Management LP Takes Position in Xenon Pharmaceuticals Inc. $XENE
Cinctive Capital Management LP has disclosed a new position in Xenon Pharmaceuticals Inc. (NASDAQ:XENE), purchasing 23,054 shares valued at approximately $926,000 in the third quarter. While institutional ownership is high at 95.45%, insiders have been net sellers in the past 90 days. The stock currently has a consensus "Buy" rating from analysts with an average price target of $71.88, despite trading near $54.66 and having recent insider selling activities.
Xenon Pharmaceuticals (NASDAQ:XENE) Price Target Cut to $63.00 by Analysts at Wedbush
Wedbush analysts have reduced their price target for Xenon Pharmaceuticals (NASDAQ:XENE) to $63.00 from $64.00, while maintaining an "outperform" rating, indicating a potential 14.1% upside. Despite this, the biopharmaceutical company has seen significant insider selling and missed its last quarterly earnings estimate, posting an EPS of -$1.31 against a consensus of -$1.20. The broader analyst consensus, however, remains a "Buy" with an average price target of $71.88, with some firms setting targets as high as $97.00.
HighVista Strategies LLC Increases Stock Holdings in Xenon Pharmaceuticals Inc. $XENE
HighVista Strategies LLC increased its stake in Xenon Pharmaceuticals Inc. by 80.2%, now holding 82,190 shares valued at $3.3 million. Other major funds like Wellington Management Group and Holocene Advisors also significantly boosted their positions, leading to approximately 95.45% institutional ownership. Despite positive developments like the completion of the Phase-3 X-TOLE2 study and a large public offering that raised $747.5 million, the company faces near-term headwinds including a 4.6% stock price decrease, negative EPS, and dilution risk from recent insider selling and the new share issuance.
Commodore Capital LP Has $108.41 Million Position in Xenon Pharmaceuticals Inc. $XENE
Commodore Capital LP reduced its stake in Xenon Pharmaceuticals Inc. (NASDAQ:XENE) by 10.7% to 2.7 million shares, now valued at $108.41 million, making it their third-largest holding despite the reduction. The article highlights positive developments for Xenon, including the completion of a Phase-3 study and a successful public offering raising $747.5M, but also notes negative sentiment due to insider selling and dilution risks. Analysts maintain a "Buy" rating with an average price target of $71.94, even as insider transactions show substantial sales by executives.
Xenon Pharmaceuticals (XENE) Climbs 31.7% as Epilepsy Treatment Moves Forward
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) saw its stock climb by 31.7% following positive clinical trial results for its epilepsy and depression treatment candidate, Azetukalner. The company plans to submit a New Drug Application (NDA) to the FDA in the third quarter of this year, after phase three trials showed a 53% seizure reduction. Following these promising results, Xenon Pharmaceuticals successfully raised $747.5 million through a public offering of common shares.
Xenon Pharmaceuticals (NASDAQ:XENE) CEO Sells $403,620.84 in Stock
Xenon Pharmaceuticals CEO Ian Mortimer sold 7,308 shares of the company's stock for $403,620.84 on March 13th, decreasing his stake by 26.84%. This sale is part of a series of large insider transactions in March and January, totaling millions of dollars. Despite the insider selling and a 4.6% stock dip, Xenon recently completed a Phase 3 study for XEN1101, secured $747.5M in a public offering, and maintains a "Buy" consensus rating with an average analyst price target of $71.94.
Xenon Pharmaceuticals (XENE) sets June 2, 2026 annual shareholder meeting and April 7 record date
Xenon Pharmaceuticals Inc. (XENE) has scheduled its 2026 annual shareholder meeting for June 2, 2026, with April 7, 2026, designated as the record date for notice and voting. The company will utilize a notice-and-access approach for both registered and non-registered investors to distribute meeting materials electronically, while still covering material distribution costs for objecting beneficial owners. This information was communicated via an 8-K SEC filing which also referenced a corresponding SEDAR+ filing in Canada.
Xenon Pharmaceuticals (NASDAQ: XENE) CLO sale covers RSU taxes
Xenon Pharmaceuticals' Chief Legal Officer, Andrea DiFabio, reported equity compensation activity including the vesting of 3,750 restricted share units (RSUs) on March 12, 2026. To cover tax withholding obligations associated with this vesting, 1,342 common shares were sold on March 13, 2026, at $55.225 per share under a pre-arranged Rule 10b5-1 "sell-to-cover" instruction. Following these transactions, DiFabio directly holds 7,301 common shares and has 11,250 RSUs remaining.
Xenon Pharmaceuticals Nets $707.7 Million in $57 Share Offering With Pre-Funded Warrants
Xenon Pharmaceuticals completed an underwritten public offering, generating approximately $707.7 million in net proceeds. The offering included common shares at $57.00 each and pre-funded warrants. J.P. Morgan and other major financial institutions led the underwriting.
Xenon Pharmaceuticals Announces Closing of $747.5 Million Upsized Public Offering Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares
Xenon Pharmaceuticals Inc. announced the closing of its upsized public offering, generating approximately $747.5 million in gross proceeds. The offering included common shares and pre-funded warrants, with the full exercise of the underwriters' option to purchase additional shares. The neuroscience-focused biopharmaceutical company specializes in drug discovery and clinical development for neurological conditions.
Xenon Pharmaceuticals Announces Closing of $747.5 Million Upsized Public Offering Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares
Xenon Pharmaceuticals Inc. has announced the closing of an upsized public offering, raising approximately $747.5 million in gross proceeds. The offering included the full exercise of the underwriters' option to purchase additional shares, totaling 12,236,843 common shares and pre-funded warrants for 877,194 common shares. The shares were priced at $57.00 each, with pre-funded warrants at $56.9999.
Xenon Pharmaceuticals Announces Closing of $747.5 Million Upsized Public Offering Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares
Xenon Pharmaceuticals Inc. announced the closing of its upsized public offering, generating approximately $747.5 million in gross proceeds. The offering included 12,236,843 common shares and pre-funded warrants, with the underwriters fully exercising their option to purchase additional shares. The funds will support the company's neuroscience-focused drug discovery and clinical development of therapeutics for conditions like epilepsy and major depressive disorder.
Xenon Pharmaceuticals (XENE) CLO sells shares to cover PSU taxes
Xenon Pharmaceuticals' Chief Legal Officer, Andrea DiFabio, reported the vesting of 7,500 Performance Share Units (PSUs) on March 9, 2026, which converted into common shares. To cover tax withholding obligations arising from this vesting, DiFabio sold 2,607 common shares on March 10, 2026, at an average price of $60.108 per share. This sale was conducted under a pre-arranged Rule 10b5-1 plan.
Xenon Pharmaceuticals Announces Pricing of Upsized $650.0 Million Public Offering
Xenon Pharmaceuticals Inc. announced the pricing of an upsized underwritten public offering valued at approximately $650.0 million. The offering includes 10,526,317 common shares at $57.00 each and 877,194 pre-funded warrants. The company has also granted underwriters an option to purchase an additional 1,710,526 common shares.
Is Xenon Pharmaceuticals (XENE) Pricing Look Compelling After Recent 37% Weekly Share Surge?
Xenon Pharmaceuticals (XENE) recently experienced a 37% weekly share surge, prompting an analysis of its valuation. A Discounted Cash Flow (DCF) model suggests the stock is significantly undervalued, while a Price-to-Book (P/B) ratio analysis indicates it's about right. The article also presents bull and bear case narratives for the company, with fair value estimates ranging from $55.40 to $100 per share.
Xenon Pharmaceuticals shares jump 40% after strong Phase 3 seizure trial results
Xenon Pharmaceuticals' shares surged by 40% following positive results from its Phase 3 epilepsy trial for its drug, XEN1101. The trial, dubbed EPIXEN, showed a statistically significant reduction in seizure frequency across all doses tested, reaching its primary endpoint. This successful outcome positions XEN1101 as a potential new therapy for focal epilepsy, reinforcing investor confidence in the company.
[144] Xenon Pharmaceuticals Inc. SEC Filing
This SEC filing is a Form 144 notice from Xenon Pharmaceuticals Inc. detailing a proposed sale of securities. The filing indicates a neutral impact and sentiment. It includes information about the issuer, the securities to be sold (Common Shares), and the acquisition details, specifically a performance share unit award vesting on March 9, 2026.
Xenon Pharmaceuticals (NASDAQ: XENE) prices $707.7M equity raise
Xenon Pharmaceuticals successfully completed an underwritten public offering, raising approximately $707.7 million in net proceeds. The offering included common shares and pre-funded warrants, with underwriters fully exercising their option for additional shares. This significant capital infusion is expected to bolster the company's financial resources, with the pre-funded warrants offering flexibility to investors.
Xenon Pharmaceuticals Inc. Prices Upsized Public Offering, Anticipated Gross Proceeds of Approximately $650 Million
Xenon Pharmaceuticals Inc. announced the pricing of an upsized public offering of common shares and pre-funded warrants, expecting to raise approximately $650 million. The offering includes 10,526,317 common shares at $57.00 each and pre-funded warrants for up to 877,194 shares at $56.9999, with an option for underwriters to purchase additional common shares. The funds will support the company's neuroscience drug discovery and clinical development programs, including its lead molecule azetukalner, for conditions like epilepsy and major depressive disorder.
Xenon Pharmaceuticals Announces Pricing of Upsized $650.0 Million Public Offering
Xenon Pharmaceuticals Inc. announced the pricing of an upsized underwritten public offering valued at approximately $650.0 million. The offering includes 10,526,317 common shares at $57.00 each and pre-funded warrants for up to 877,194 common shares at $56.9999 per warrant. The company has also granted underwriters a 30-day option to purchase an additional 1,710,526 common shares.
Biotech Xenon raises $650M in stock sale at $57 a share
Xenon Pharmaceuticals announced the pricing of an upsized underwritten public offering, raising approximately $650.0 million in gross proceeds. The offering includes 10,526,317 common shares and pre-funded warrants for 877,194 shares, priced at $57.00 per common share. The closing is expected around March 12, 2026, and the funds will support the neuroscience-focused biopharmaceutical company's drug discovery and clinical development activities.
XENE: HC Wainwright Raises Price Target for Xenon Pharmaceuticals | XENE Stock News
HC Wainwright & Co. has affirmed its 'Buy' rating for Xenon Pharmaceuticals (XENE) and increased its price target from $53.00 to $74.00, representing a significant 39.62% jump. This follows a trend of several analysts raising their price targets for Xenon, which specializes in neuroscience biopharmaceuticals for neurological and psychiatric disorders. Despite these positive revisions, the average one-year price target from 18 analysts suggests a potential 10.52% downside from the current price of $62.68.
Guggenheim Maintains Buy on Xenon Pharmaceuticals Inc. (XENE) March 2026
Guggenheim, Bank of America Securities, and Jefferies all reiterated "Buy" ratings on Xenon Pharmaceuticals Inc. (XENE) on March 9, 2026. Guggenheim raised its price target to $90, Bank of America to $77, and Jefferies indicated a potential 50-75% upside. These actions reflect analyst confidence in XENE's future performance, but investors are advised to consider risks and individual research.
Xenon Pharmaceuticals Launches $500 Million Public Share Offering
Xenon Pharmaceuticals (XENE) has initiated an underwritten public offering to raise $500 million in common shares, with an additional $75 million potential overallotment. This move aims to strengthen the company's financial position and support its neuroscience drug pipeline, despite potentially causing near-term share dilution for investors. Spark, TipRanks’ AI Analyst, rates XENE as Neutral, citing a strong balance sheet and positive earnings-call outlook balanced by weak operating financials.
Guggenheim raises Xenon Pharmaceuticals stock price target on trial data
Guggenheim raised its price target on Xenon Pharmaceuticals (NASDAQ:XENE) to $90 from $60, maintaining a Buy rating after positive Phase 3 clinical trial results for its epilepsy treatment, azetukalner. The X-TOLE2 study met its primary and secondary endpoints, outperforming previous trials, leading to a surge in the stock price and increased analyst confidence. Xenon Pharmaceuticals plans to submit its New Drug Application in Q3 2026, and the data will be presented at the American Academy of Neurology Annual Meeting.
